{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009829","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.285718+00:00","generated_at":"2026-06-04T22:34:43.911674+00:00","sec_items":["5.02","8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mira Pharmaceuticals board overhaul: 4 resignations, new directors, CSO replaced by advisor","bullets":["Directors Talhia Tuck, Brad Kroenig, Hugh McColl resigned March 9; Chairman Chris Chapman resigned to focus on Telomir Pharma.","New board: CEO Erez Aminov named Chairman; Dr. Matthew Del Giudice, Dr. Denil Shekhat, Ned MacPherson appointed.","President & CSO Dr. Adam Kaplin resigned March 7; company hired Dr. Itzchak Angel as Chief Scientific Advisor via APCT.","Dr. Angel has 30+ yrs pharma experience, helped develop Ambien, Xatral; will assist with IND preparation and regulatory affairs.","Restructuring aims to strengthen clinical/regulatory expertise for future IND filing for product candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009829","json":"https://secwatch.observer/filing/0001493152-24-009829.json","markdown":"https://secwatch.observer/filing/0001493152-24-009829.md","text":"https://secwatch.observer/filing/0001493152-24-009829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:34:43.911674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ca0ed1ce7","claim":"Matthew P. Del Giudice was appointed as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"239f62d0c5","claim":"Hugh McColl resigned as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"31404c5a78","claim":"Chris Chapman resigned as Executive Chairman at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Also on March 9, 2024, Dr. Chris Chapman notified the Board and senior Company management of his resignation both as Executive Chairman and as an employee of the Company, effective immediately, citing his desire to focus his time on his role as Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"82e0784358","claim":"Ned MacPherson was appointed as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"83411cd64d","claim":"Erez Aminov was appointed as Chairman of the Board at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"c5ff08a74f","claim":"Brad Kroenig resigned as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"eeae8efd7d","claim":"Denil N. Shekhat was appointed as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"On March 13, 2024, the remaining members of the Board (Erez Aminov and Michael Jerman) unanimously approved the appointment of (i) Mr. Aminov, the Company’s Chief Executive Officer, as Chairman of the Board and (ii) Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat and Mr. Ned MacPherson as members of the Board, to fill the vacancies on the Board occasioned by the resignations from the Board described above","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f6532b5e8f","claim":"Talhia Tuck resigned as Director at MIRA PHARMACEUTICALS, INC..","evidence_excerpt":"Ms. Talhia Tuck, Mr. Brad Kroenig and Mr. Hugh McColl, each voluntarily resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224009829/0001493152-24-009829-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}